After mild traumatic brain injury (TBI), a molecule called complement factor C1q may play a role in the secondary effects of brain injury, such as sleep disruption, epileptic activity, and ...

Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

An announcement from Annexon Biosciences ( (ANNX) ) is now available.

Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 27 (Jul. 6, 2004), pp. 10127-10131 (5 pages) The lectin complement pathway in innate immunity is closely ...

This story was updated on February 5, 2019. Just when you thought ApoE biology couldn’t get any more complicated, scientists have discovered a new function for this apolipoprotein. According to a ...

Investigators working at Gladstone Institutes reported new insights into sleep disturbances and seizures that can be a late consequence of even mild traumatic brain injuries (TBI), and how we may one ...

SAN FRANCISCO -- A neuroprotective approach to geographic atrophy (GA) had a time-dependent effect on lesion growth and a significant impact on visual acuity, an early study showed. Overall, the ...

Anti-C1q antibodies were present among 74.3% of patients with immunoglobulin G4-related disease. Anti-C1q antibodies are highly prevalent among patients with immunoglobulin G4-related disease (IgG4-RD ...